Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy.

ABSTRACT: The residual cancer burden index was developed as a method to quantify residual disease ranging from pathological complete response to extensive residual disease. The aim of this study was to evaluate the inter-Pathologist reproducibility in the residual cancer burden index score and category, and in their long-term prognostic utility. Pathology slides and pathology reports of 100 cases from patients treated in a randomized neoadjuvant trial were reviewed independently by five pathologists. The size of tumor bed, average percent overall tumor cellularity, average percent of the in situ cancer within the tumor bed, size of largest axillary metastasis, and number of involved nodes were assessed separately by each pathologist and residual cancer burden categories were assigned to each case fo

SUBMITTER: Peintinger F 

PROVIDER: S-EPMC4830087 | biostudies-literature | 2015 Jul

REPOSITORIES: biostudies-literature